Individualised proteome profiling of human endometrial tumours improves detection of new prognostic markers

British Journal of Cancer

Volumn 109, Issue 3, 2013, Pages 704-713

  Attarha, S ^a   Andersson, S ^a   Mints, M ^a   Souchelnytskyi, S ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN MST1; PROTEIN PKN1; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; ENDOMETRIUM CANCER; ENDOMETRIUM TUMOR; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SYSTEMS BIOLOGY; TISSUE MICROARRAY;

DOWN-REGULATION; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INDIVIDUALIZED MEDICINE; PROGNOSIS; PROTEIN KINASE C; PROTEIN-SERINE-THREONINE KINASES; PROTEOME; PROTEOMICS; SYSTEMS BIOLOGY;

EID: 84883158627     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.359     Document Type: Article

References (35)

1. Adam L, Vadlamudi R, Mandal M, Chernoff J, Kumar R (2000) Regulation of microfilament reorganization and invasiveness of breast cancer cells by kinase dead p21-activated kinase-1. J Biol Chem 275(16): 12041-12050.
2. Attarha S, Mints M, Andersson S, Souchelnytskyi S (2011) Endometrial cancer and application of proteomics. Exp Oncol 33: 174-177.
3. Bork P, Jensen LJ, von Mering C, Ramani A, Lee I, Marcotte EM (2004) Protein interaction networks from yeast to human. Curr Opin Struct Biol 14(3): 292-299.
4. Carter JH, Douglass LE, Deddens JA, Colligan BM, Bhatt TR, Pemberton JO, Konicek S, Hom J, Marshall M, Graff JR (2004) Pak-1 expression increases with progression of colorectal carcinomas to metastasis. Clin Cancer Res 10(10): 3448-3456.
5. Creasman WT (1993) Prognostic significance of hormone receptors in endometrial cancer. Cancer 71: 1467-1470.
6. Dedes KJ, Wetterskog D, Ashworth A, Kaye SB, Reis-Filho JS (2011) Emerging therapeutic targets in endometrial cancer. Nat Rev Clin Oncol 8: 261-271.
7. Doll A, Abal M, Rigau M, Monge M, Gonzalez M, Demajo S, Colás E, Llauradó M, Alazzouzi H, Planagumá J, Lohmann MA, Garcia J, Castellvi S, Ramon y Cajal J, Gil-Moreno A, Xercavins J, Alameda F, Reventós J (2008) Novel molecular profiles of endometrial cancer-new light through old windows. J Steroid Biochem Mol Biol 108: 221-229.
8. Engelsen IB, Stefansson I, Akslen LA, Salvesen HB (2006) Pathologic expression of p53 or p16 in preoperative curettage specimens identifies high-risk endometrial carcinomas. Am J Obstet Gynecol 195: 979-986.
9. Galgano MT, Conaway M, Spencer AM, Paschal BM, Frierson Jr HF (2009) PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma. HumPathol 40(10): 1434-1440.
10. Hucka M, Finney A, Sauro HM, Bolouri H, Doyle JC, Kitano H, Arkin AP, Bornstein BJ, Bray D, Cornish-Bowden A, Cuellar AA, Dronov S, Gilles ED, Ginkel M, Gor V, Goryanin II, Hedley WJ, Hodgman TC, Hofmeyr JH, Hunter PJ, Juty NS, Kasberger JL, Kremling A, Kummer U, Le Novère N, Loew LM, Lucio D, Mendes P, Minch E, Mjolsness ED, Nakayama Y, Nelson MR, Nielsen PF, Sakurada T, Schaff JC, Shapiro BE, Shimizu TS, Spence HD, Stelling J, Takahashi K, Tomita M, Wagner J, Wang J. SBML Forum (2003) The systems biology markup language (SBML): a medium for representation and exchange of biochemical network models. Bioinformatics 19(4): 524-531.
11. Kauppila AJ, Isotalo HE, Kivinen ST, Vihko RK (1986) Prediction of clinical outcome with estrogen and progestin receptor concentrations and their relationships to clinical and histopathological variables in endometrial cancer. Cancer Res 46: 5380-5384.
12. Koboldt D, Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418): 61-70.
13. Kohlmann A, Grossmann V, Haferlach T. (2012) Integration of nextgeneration sequencing into clinical practice: are we there yet? Semin Oncol 39(1): 26-36.
14. Lan N, Montelione GT, Gerstein M. (2003) Ontologies for proteomics: towards a systematic definition of structure and function that scales to the genome level. Curr Opin Chem Biol 7(1): 44-54.
15. Levan K, Partheen K, Osterberg L, Olsson B, Delle U, Eklind S, Horvath G (2010) Identification of a gene expression signature for survival prediction in type I endometrial carcinoma. Gene Expr 14(6): 361-370.
16. Liu F, Li X, Wang C, Cai X, Du Z, Xu H, Li F (2009) Downregulation of p21-activated kinase-1 inhibits the growth of gastric cancer cells involving cyclin B1. Int J Cancer 125(11): 2511-2519.
17. Metzger E, Müller JM, Ferrari S, Buettner R, Schüle R (2003) A novel inducible transactivation domain in the androgen receptor: implications for PRK in prostate cancer. EMBO J 22(2): 270-280.
18. Mhawech-Fauceglia P, Wang D, Kesterson J, Clark K, Monhollen L, Odunsi K, Lele S, Liu S (2010) Microarray analysis reveals distinct gene expression profiles among different tumor histology, stage and disease outcomes in endometrial adenocarcinoma. PLoS One 5(11): e15415.
19. Minoo P, Zlobec I, Baker K, Tornillo L, Terracciano L, Jass JR, Lugli A (2007) Prognostic significance of mammalian sterile20-like kinase 1 in colorectal cancer. Mod Pathol 20(3): 331-338.
20. Monge M, Colas E, Doll A, Gil-Moreno A, Castellvi J, Diaz B, Gonzalez M, Lopez-Lopez R, Xercavins J, Carreras R, Alameda F, Canals F, Gabrielli F, Reventos J, Abal M (2009) Proteomic approach to ETV5 during endometrial carcinoma invasion reveals a link to oxidative stress. Carcinogenesis 30(8): 1288-1297.
21. Ng YK, Lau WS, Lui VW, Cheng AS, Ng PK, Tsui SK, Cheung YS, Lai PB (2013) Full-length Mst1 exhibits growth promoting function in human hepatocellular carcinoma cells. FEBS Lett 587(5): 496-503.
22. Pradhan M, Abeler VM, Danielsen HE, Sandstad B, Tropé CG, Kristensen GB, Risberg B (2012) Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium. Ann Oncol 23: 1178-1178.
23. Salvesen HB, Carter SL, Mannelqvist M, Dutt A, Getz G, Stefansson IM, Raeder MB, Sos ML, Engelsen IB, Trovik J, Wik E, Greulich H, Bø TH, Jonassen I, Thomas RK, Zander T, Garraway LA, Oyan AM, Sellers WR, Kalland KH, Meyerson M, Akslen LA, Beroukhim R (2009) Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3kinase activation. Proc Natl Acad Sci USA 106(12): 4834-4839.
24. Salvesen HB, Haldorsen IS, Trovik J (2012) Markers for individualised therapy in endometrial carcinoma. Lancet Oncol 13(8): e353-e361.
25. Salvesen HB, Iversen OE, Akslen LA (1999) Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population based endometrial carcinoma study. J Clin Oncol 17: 1382-1390.
26. Saunders NA, Simpson F, Thompson EW, Hill MM, Endo-Munoz L, Leggatt G, Minchin RF, Guminski A. (2012) Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives. EMBO Mol Med 4(8): 675-684.
27. Sharon D, Chen R, Snyder M (2010) Systems biology approaches to disease marker discovery. Dis Markers 28: 209-224.
28. Souchelnytskyi S (2005) Bridging proteomics and systems biology: what are the roads to be traveled? Proteomics 5(16): 4123-4137.
29. Staff AC, Trovik J, Eriksson AG, Wik E, Wollert KC, Kempf T, Salvesen HB (2011) Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer. Clin Cancer Res 17: 4825-4833.
30. Susini T, Amunni G, Molino C, Carriero C, Rapi S, Branconi F, Marchionni M, Taddei G, Scarselli G (2007) Ten-year results of a prospective study on the prognostic role of ploidy in endometrial carcinoma: dNA aneuploidy identifies high-risk cases among the so-called 'low-risk' patients with well and moderately differentiated tumors. Cancer 109: 882-890.
31. Tian Q, Price ND, Hood L. (2012) Systems cancer medicine: towards realization of predictive, preventive, personalized and participatory (P4) medicine. J Intern Med 271(2): 111-121.
32. Westin SN, Broaddus RR (2012) Personalized therapy in endometrial cancer. Cancer Biol Ther 13(1): 1-13.
33. Wilkins MR, Appel RD, Van Eyk JE, Chung MC, Görg A, Hecker M, Huber LA, Langen H, Link AJ, Paik YK, Patterson SD, Pennington SR, Rabilloud T, Simpson RJ, Weiss W, Dunn MJ. (2006) Guidelines for the next 10 years of proteomics. Proteomics 6(1): 4-8.
34. Yi Z, Jingting C, Yu Z (2009) Proteomics reveals protein profile changes in cyclooxygenase-2 inhibitor-treated endometrial cancer cells. Int J Gynecol Cancer 19: 326-333.
35. Zakharchenko O, Greenwood C, Lewandowska A, Hellman U, Alldridge L, Souchelnytskyi S (2011) Meta-data analysis as a strategy to evaluate individual and common features of proteomic changes in breast cancer. Cancer Genomics Proteomics 8(1): 1-14.